Silibinin inhibits prostate cancer cells- and RANKL-induced osteoclastogenesis by targeting NFATc1, NF-κB and AP-1 activation in RAW264.7 cells

Currently, there are limited therapeutic options against bone metastatic prostate cancer (PCA), which is primarily responsible for high mortality and morbidity in PCA patients. Enhanced osteoclastogenesis is an essential feature associated with metastatic PCA in the bone microenvironment. Silibinin,...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Kavitha, Chandagirikoppal V., Deep, Gagan, Gangar, Subhash C., Jain, Anil K., Agarwal, Chapla, Agarwal, Rajesh
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2012
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC3925459/
https://ncbi.nlm.nih.gov/pubmed/23115104
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/mc.21959
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk